Stroke prevention in patients with atrial fibrillation (AF) is one pillar of the management of
this common arrhythmia. Substantial advances in the epidemiology and associated …

The concept of frailty, now being adopted in most medical disciplines, is attracting growing
interest in neurology. Every day, most neurologists care for patients with varying degrees of …

Abstract Background and Aims Reports of outcomes after atrial fibrillation (AF) diagnosis are
conflicting. The aim of this study was to investigate mortality and hospitalization rates …

Aims Data on non-vitamin K antagonist oral anticoagulants (NOACs) use in patients with
atrial fibrillation (AF) and frailty are scarce. Therefore, the impact of frailty on AF-related …

There is an escalating trend in both the incidence and prevalence of atrial fibrillation (AF).
AF is linked to numerous other comorbidities, contributing to the emergence of …

Aims Heart failure (HF) is a risk factor for major adverse events in atrial fibrillation (AF).
Whether this risk persists on non-vitamin K antagonist oral anticoagulants (NOACs) and …

Anticoagulants are a cornerstone of treatment in atrial fibrillation. Nowadays, direct oral
anticoagulants (DOACs) are extensively used for this condition in developed countries …

Aims Atrial fibrillation (AF) has been associated with functional impairment. However, the
role exerted by AF on the long-term trajectories of functional mobility remains to be …

Objective To investigate prevalence and predictors of oral anticoagulant therapy (OAT)
deprescribing in older inpatients with atrial fibrillation (AF), and its association with 1-year …

Non-vitamin K antagonist oral anticoagulants (NOACs) have substantially improved
anticoagulation. However, data on NOAC use among elderly patients are scarce. We sought …